Editas Medicine (EDIT) News Today $3.92 +0.03 (+0.77%) Closing price 04:00 PM EasternExtended Trading$3.92 0.00 (-0.03%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EDIT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Institutions profited after Editas Medicine, Inc.'s (NASDAQ:EDIT) market cap rose US$47m last week but individual investors profited the mostSeptember 30 at 11:58 AM | finance.yahoo.comEditas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo ProgramSeptember 29, 2025 | finance.yahoo.comWall Street Zen Upgrades Editas Medicine (NASDAQ:EDIT) to HoldSeptember 28, 2025 | americanbankingnews.comAnalysts Set Editas Medicine, Inc. (NASDAQ:EDIT) PT at $5.10September 28, 2025 | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) Upgraded by Wall Street Zen to Hold RatingSeptember 26, 2025 | marketbeat.comEditas Medicine, Inc. $EDIT Shares Sold by Goldman Sachs Group Inc.September 25, 2025 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Hold" by AnalystsSeptember 25, 2025 | marketbeat.comEditas Medicine, Inc. $EDIT Shares Bought by Ieq Capital LLCSeptember 9, 2025 | marketbeat.comEditas Medicine (EDIT) Receives a Hold from JonesTradingSeptember 8, 2025 | theglobeandmail.com316,614 Shares in Editas Medicine, Inc. $EDIT Acquired by Nuveen LLCSeptember 8, 2025 | marketbeat.comBrokers Offer Predictions for Editas Medicine Q3 EarningsSeptember 7, 2025 | marketbeat.comEditas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)September 6, 2025 | benzinga.comWells Fargo & Company Increases Editas Medicine (NASDAQ:EDIT) Price Target to $4.00September 5, 2025 | marketbeat.comEditas Medicine price target raised to $4 from $3 at Wells FargoSeptember 3, 2025 | msn.comCan Editas Medicine (NASDAQ:EDIT) Afford To Invest In Growth?September 2, 2025 | finance.yahoo.comEditas Medicine, Inc. - Special CallSeptember 2, 2025 | seekingalpha.comEditas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development CandidateSeptember 2, 2025 | globenewswire.comEditas Medicine (NASDAQ:EDIT) Stock Crosses Below 50 Day Moving Average - Time to Sell?September 1, 2025 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Hold" from AnalystsSeptember 1, 2025 | marketbeat.comEditas Medicine to Host Webinar Announcing Lead In Vivo Development CandidateAugust 28, 2025 | globenewswire.comEditas Medicine to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Editas Medicine (EDIT), Tilray (TLRY)August 27, 2025 | theglobeandmail.comEditas Medicine (NASDAQ:EDIT) Downgraded to Sell Rating by Wall Street ZenAugust 17, 2025 | marketbeat.comWhy Editas Medicine Stock Was Skyrocketing This WeekAugust 16, 2025 | msn.comEditas Medicine (NASDAQ:EDIT) Posts Earnings Results, Misses Expectations By $0.22 EPSAugust 15, 2025 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Price Target Raised to $6.00August 15, 2025 | marketbeat.comEditas Medicine price target raised to $6 from $4 at BairdAugust 13, 2025 | msn.comEditas Medicine, Inc.: Editas Medicine Announces Second Quarter 2025 Results and Business UpdatesAugust 13, 2025 | finanznachrichten.deCan This Beaten-Down Stock Bounce Back?August 12, 2025 | msn.comEditas Medicine Announces Second Quarter 2025 Results and Business UpdatesAugust 12, 2025 | globenewswire.comGinkgo Bioworks files $500M mixed securities shelfAugust 8, 2025 | msn.comXTX Topco Ltd Buys 370,325 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)August 7, 2025 | marketbeat.comInsider Selling: Editas Medicine, Inc. (NASDAQ:EDIT) EVP Sells $12,751.29 in StockAugust 5, 2025 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) EVP Sells $12,751.29 in StockAugust 5, 2025 | insidertrades.comEditas Medicine (EDIT) Expected to Announce Earnings on WednesdayJuly 31, 2025 | marketbeat.comEditas Medicine: Primed For An Unlikely Comeback? It's Not ImpossibleJuly 30, 2025 | seekingalpha.comEditas Medicine (NASDAQ:EDIT) Raised to Hold at Wall Street ZenJuly 26, 2025 | marketbeat.comEditas Surpasses Therapeutic Gene Editing Threshold in New Preclinical DataJuly 3, 2025 | msn.comEditas Medicine Inc EDIT Company Vitals - U.S. NewsJuly 1, 2025 | money.usnews.comSickle Cell Disease Treatment Market Set for Robust Growth Through 2034, Driven by Recent Clinical Pipeline Developments | DelveInsightJuly 1, 2025 | theglobeandmail.comWall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?June 28, 2025 | fool.comEditas Medicine Inc. Annual Cash Flow Statement - MarketWatchJune 25, 2025 | marketwatch.comEditas Medicine Inc.June 25, 2025 | barrons.comGene editors steady despite latest leadership shake-up at FDAJune 20, 2025 | msn.comLilly-Verve deal sends gene editing stocks higherJune 17, 2025 | msn.comEditas Medicine Is Great. Here's Why You Shouldn't Buy It.June 17, 2025 | msn.comEditas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Hold" from BrokeragesJune 17, 2025 | marketbeat.comEditas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in JuneJune 12, 2025 | globenewswire.comRFK Jr. Just Supercharged These 2 Biotech Penny StocksJune 11, 2025 | msn.comBank of America Corp DE Reduces Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)June 11, 2025 | marketbeat.com Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EDIT Media Mentions By Week EDIT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EDIT News Sentiment▼0.340.52▲Average Medical News Sentiment EDIT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EDIT Articles This Week▼55▲EDIT Articles Average Week Get the Latest News and Ratings for EDIT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Editas Medicine and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Beam Therapeutics News Today CRISPR Therapeutics News Today Intellia Therapeutics News Today Amphastar Pharmaceuticals News Today atai Life Sciences News Today Tourmaline Bio News Today Enliven Therapeutics News Today Amylyx Pharmaceuticals News Today CureVac News Today Oric Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EDIT) was last updated on 10/3/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
